|
|
Evaluation of 1p and 19q chromosomal alterations in oligodendroglial neoplasms
using microdissection and microsatellite analysis technique and correlations
with response to chemotherapy
E. Franceschi, G. Cavallo, A. Paioli, L. Scopece, R. Degli Esposti, E. Leonardi,
F. Spagnolli, A. M. Cremonini, A. Pession, L. Crino
Bellaria Hospital, Bologna, Italy; Bufalini Hospital, Cesena,
Italy
Background. Oligodendroglial tumors are chemosensitive diseases.
The
evaluation by fluorescence in situ hybridization has been used to assess 1p and
19q alterations that are considered the best chemosensitivity test in these
tumors.
Here we show another way to evaluate 1p and 19q chromosomal alterations
by using microsatellite analysis that could be considered an useful tool in
translational research for the accuracy of this method.
Methods. Patients
DNA was extracted from peripheral blood to define the wild type allelic
condition, instead tumoral DNA was obtained from laser microdissected cells.
We
analized 4 microsatellites on Chr1p and 3 on Chr19q (chosen from sequences
described by J.M. Nigro et al., Am J Path 2001); for each locus loss of
heterozigosity (LOH), allelic imbalance or chromosomal instability were defined
based on allelic peaks pattern.
Chemotherapic regimens allowed were: PCV or
Temozolomide or Carboplatin-Etoposide (CE).
Results. At the time of
abstract submission we evaluated 21 oligodendroglial tumor adult patients: 4
with oligodendroglioma, 12 with anaplastic oligodendroglioma and 5 with mixed
oligoastrocytoma (2 G2 and 3 G3).
In 10 patients both primary and recurrent
disease samples were available.
16/21 patients were treated with chemotherapy.
PCV combination was used as first line in 1 patient, Temozolomide was used as
first line in 9 patients and CE combination was used as first line in 6
patients.
Conclusions. The evaluation of 1p and 19q status by
microsatellite analysis is feasible and provides useful informations about
oligodendroglial tumors.
Further results and correlations with response to
radiotherapy and chemotherapy, and differences in 1p and 19q LOH pattern between
primary and recurrence will be presented at the meeting.
|
|
|
WT
|
LOH1p
|
LOH 19q
|
LOH 1p+19q
|
Allelic imbalance
|
Chromosomal instability
|
|
O2
|
2 - 50%
|
0
|
0
|
2 - 50%
|
1
|
1
|
|
O3
|
2 - 17%
|
2 - 17%
|
1 - 8%
|
7 - 58%
|
2
|
2
|
|
OA2
|
1 - 50%
|
0
|
0
|
1 - 50%
|
0
|
0
|
|
OA3
|
2 - 66%
|
0
|
0
|
1 - 33%
|
0
|
0
|
Copyright 2004 American Society of Clinical Oncology All rights
reserved worldwide.
Source: http://www.asco.org/ac/1,1003,_12-002636-00_18-0026-00_19-002696,00.asp
|